base metals investing Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
base metals investing Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
base metals investing Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
base metals investing Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia
base metals investing Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026
base metals investing Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer
base metals investing Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
base metals investing Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026
Golconda Gold Announces the Election of Paul Olmsted and James Colter Eadie to the Board of Directors
Standard Uranium Initiates 2026 Drill Program at the Davidson River Uranium Project, Southwest Athabasca Basin
Nuvau Minerals commences PEA study to advance Matagami restart strategy, which includes a fully permitted critical metals mine
